1 ILD) in a large cohort of patients with anti-Jo-1 antibodies.

2 A topoisomerase I), anticentromere, and anti-Jo-1 antibodies.

3 vealed a modest correlation between the anti-Jo-1 antibody level and the serum creatine kinase (CK) l

4  have examined the relationship between anti-Jo-1 antibody levels and myositis disease activity, demo

5 e used to identify associations between anti-Jo-1 antibody levels and organ-specific disease activity

6 cally reexamine the association between anti-Jo-1 antibody levels and various disease manifestations

7  with idiopathic inflammatory myopathy, anti-Jo-1 antibody levels correlated modestly with muscle and

8 ses of 11 patients with serial samples, anti-Jo-1 antibody levels correlated significantly with CK le

9 ngitudinal subset of patients that link anti-Jo-1 antibody levels to muscle, joint, lung, and global

10                                   Serum anti-Jo-1 antibody levels were quantified using 2 independent

11 ically significant associations between anti-Jo-1 antibody-positive ILD and elevated serum levels of

12 d disease-specific associations between anti-Jo-1 antibody-positive ILD and serum levels of CRP as we

13 sess the serum proteins associated with anti-Jo-1 antibody-positive ILD.

14 dies determined the existence of ILD in anti-Jo-1 antibody-positive individuals whose data were accum

15                            Among the 90 anti-Jo-1 antibody-positive individuals with sufficient clini

16                 In this large cohort of anti-Jo-1 antibody-positive individuals, the incidence of ILD

17 ectional assessment of 81 patients with anti-Jo-1 antibody revealed a modest correlation between the

18                                              Jo-1 antibody was present in 19 (38%) of 50 patients tes